ARTICLE | Emerging Company Profile
Treating CRPC failures
Innocrin's VT-464 combines Xtandi, Zytiga MOA; could treat CRPC failures
November 17, 2014 8:00 AM UTC
Innocrin Pharmaceuticals Inc. has a Phase II compound that combines the mechanisms of Xtandi enzalutamide and Zytiga abiraterone but shows efficacy in castration-resistant prostate cancer patients who have failed or have de novo resistance to the two marketed drugs.
Innocrin spun out of antifungal company Viamet Pharmaceuticals Inc. last month to develop VT-464 and related cancer compounds identified using Viamet's database of metal-binding groups...